Hummayun Ismail, MD
Pulmonary Disease · Newark, DENPI 1962422469
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by GSK at 33.3% of the total. That places this record below the midpoint for pulmonary disease clinicians in DE, where the typical reported total is $1,477.
Across 14 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$86
- Inspire Medical Systems, Inc.$57
- Boehringer Ingelheim$33
- Tactile Systems Technology Inc$32
- Mylan Specialty L.p.$25
- Grifols USA, LLC$14
- plus $12 from 1 others
Across 27 payments — averaging $7637.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$206K
What the payments were for
- Food & beverage$24996%
- Education$124%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $86 |
| Inspire Medical Systems, Inc. | 2 | $57 |
| Boehringer Ingelheim | 2 | $33 |
| Tactile Systems Technology Inc | 1 | $32 |
| Mylan Specialty L.p. | 1 | $25 |
| Grifols USA, LLC | 1 | $14 |
| AstraZeneca | 1 | $12 |
How this compares
$260 in reported general payments places this provider in the 25th percentile of 39 pulmonary disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 351 | $294,887 |
| Breo ElliptaFluticasone/Vilanterol | 477 | $259,805 |
| OfevNintedanib Esylate | 14 | $181,952 |
| Spiriva HandihalerTiotropium Bromide | 182 | $124,302 |
| Incruse ElliptaUmeclidinium Bromide | 169 | $83,223 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 73 | $51,328 |
| Ambrisentan | 13 | $48,157 |
| EliquisApixaban | 59 | $42,997 |
| Tiotropium Bromide | 77 | $39,940 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 159 | $38,730 |
| Spiriva RespimatTiotropium Bromide | 55 | $36,556 |
| XolairOmalizumab | 12 | $32,757 |
| SymbicortBudesonide/Formoterol Fumarate | 97 | $32,621 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 758 | $23,157 |
| Arnuity ElliptaFluticasone Furoate | 67 | $19,302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $86 | $708,5461,137 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $33 | $218,50769 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $12 | $50,562126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 39 pulmonary disease providers in Delaware.
Other pulmonary disease in Newark
- Albert RizzoNewark$162K
- Haroon RajaNewark$44K
- Ismael MatusNewark$27K
- Naveed HasanNewark$3K
- Theodora FynnNewark$2K
- Sam ThomasNewark$2K
- Irene SwiftNewark$2K
- Donald CollinsNewark$2K
- Sajjad AhmadNewark$749
- Sonali BishnoiNewark$686
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.